NASDAQ:APM Aptorum Group (APM) Stock Price, News & Analysis $3.63 +0.13 (+3.71%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.54▼$3.6350-Day Range$3.32▼$5.0052-Week Range$1.35▼$17.49Volume5,078 shsAverage Volume1.09 million shsMarket Capitalization$18.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Aptorum Group alerts: Email Address Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About Aptorum Group Stock (NASDAQ:APM)Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Read More APM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APM Stock News HeadlinesJuly 26 at 5:40 AM | americanbankingnews.comAptorum Group Limited (NASDAQ:APM) Short Interest UpdateApril 30, 2024 | businesswire.comAptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business UpdateJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.March 21, 2024 | finance.yahoo.comAptorum Group Limited (APM)March 12, 2024 | cnn.comAptorum Group Limited Class AMarch 6, 2024 | finance.yahoo.comAptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy BusinessMarch 6, 2024 | investorplace.com5 Investors Betting Big on Aptorum (APM) GroupMarch 6, 2024 | investorplace.comWhy Is Aptorum (APM) Stock Up 346% Today?July 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.February 22, 2024 | investing.comAptorum Group Ltd Class A (APM)December 30, 2023 | lse.co.ukAptorum Group Cl A Share ChatDecember 26, 2023 | seekingalpha.comAptorum Group GAAP EPS of -$1.43, revenue of $0.43MDecember 22, 2023 | finance.yahoo.comAptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023November 16, 2023 | finance.yahoo.comAptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023November 9, 2023 | morningstar.comAptorum Group Ltd Class A APMSeptember 14, 2023 | benzinga.comAutism Summit Garners Over 30,000 Attendees: APM Announces Date of its Upcoming ConferenceAugust 8, 2023 | finance.yahoo.comAPM - Aptorum Group LimitedJune 27, 2023 | finanznachrichten.deAptorum Group Limited: Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaSee More Headlines Receive APM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptorum Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Estimated)7/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APM CUSIPN/A CIK1734005 Webwww.aptorumgroup.com Phone442080929299FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.20 Current Ratio1.18 Quick Ratio1.18 Sales & Book Value Annual Sales$430,000.00 Price / Sales43.37 Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book1.21Miscellaneous Outstanding Shares5,180,000Free Float1,866,000Market Cap$18.65 million OptionableNot Optionable Beta1.50 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Chung Yuen Huen (Age 44)Founder, CEO & Non-Executive Director Comp: $164kMr. Martin Siu (Age 45)Head of Finance Comp: $92.31kKey CompetitorsEupraxia PharmaceuticalsNASDAQ:EPRXvTv TherapeuticsNASDAQ:VTVTSELLAS Life Sciences GroupNASDAQ:SLSJATT AcquisitionNYSE:JATTBioLineRxNASDAQ:BLRXView All CompetitorsInstitutional OwnershipMurchinson Ltd.Bought 14,000 shares on 5/16/2024Ownership: 0.270%View All Institutional Transactions APM Stock Analysis - Frequently Asked Questions How have APM shares performed this year? Aptorum Group's stock was trading at $2.45 at the beginning of the year. Since then, APM stock has increased by 48.2% and is now trading at $3.63. View the best growth stocks for 2024 here. When did Aptorum Group's stock split? Aptorum Group's stock reverse split on the morning of Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Aptorum Group? Shares of APM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aptorum Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptorum Group investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO) and This page (NASDAQ:APM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptorum Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptorum Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.